Recent Study: Diabetic Retinopathy - Pipeline Review, H2 2013

From: Fast Market Research, Inc.
Published: Thu Oct 24 2013

Global Markets Direct's, 'Diabetic Retinopathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy. Diabetic Retinopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Full Report Details at


* A snapshot of the global therapeutic scenario for Diabetic Retinopathy.
* A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Diabetic Retinopathy pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Oxford BioMedica plc, Novagali Pharma SA, Antisense Therapeutics Limited, Lpath, Inc., BioDiem Ltd, RegeneRx Biopharmaceuticals, Inc., ThromboGenics NV, R-Tech Ueno, Ltd., Paloma Pharmaceuticals, Inc., Acucela Inc., OcuCure Therapeutics, Inc., Gene Signal International SA., Promedior, Inc., Inotek Pharmaceuticals Corporation, Angstrom Pharmaceuticals, Inc., FirstString Research, Inc., Sirnaomics, Inc., Resolvyx Pharmaceuticals, Inc, Stelic Institute & Co., Centocor Ortho Biotech, Inc., EyeCyte, Inc., Vascular Pharmaceuticals, Inc., PanOptica, Inc., Targa Therapeutics Corp., EyeGene, Inc., America Stem Cell, Inc., Ampio Pharmaceuticals, Inc.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Diabetic Nephropathy - Pipeline Review, H2 2013
- Diabetic Neuropathy - Pipeline Review, H2 2013
- Diabetic Foot Ulcers - Pipeline Review, H2 2013
- Diabetic Retinopathy - Pipeline Review, H1 2013
- Diabetic Gastroparesis - Pipeline Review, H2 2013
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »